% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • homebuilder_watcher homebuilder_watcher Jan 15, 2013 8:27 AM Flag

    Stock up on new coverage by Credit Suisse, Buy and $7 target

    Credit Suisse Assumes Coverage on Sunesis Pharmaceuticals (SNSS)
    Posted by Kristian Gore on Jan 15th, 2013 // No Comments

    Credit Suisse assumed coverage on shares of Sunesis Pharmaceuticals (NASDAQ: SNSS) in a research note issued to investors on Tuesday. The firm issued an outperform rating and a $7.00 target price on the stock.

    Separately, analysts at Wells Fargo initiated coverage on shares of Sunesis Pharmaceuticals in a research note to investors on Wednesday, December 19th. They set an outperform rating on the stock.

    Sunesis Pharmaceuticals opened at 4.00 on Tuesday. Sunesis Pharmaceuticals has a 1-year low of $1.23 and a 1-year high of $6.85. The stock’s 50-day moving average is currently $4.32. The company’s market cap is $206.0 million.

    Sunesis Pharmaceuticals last released its earnings data on Thursday, November 8th. The company reported ($0.37) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.26. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $4.17 million. During the same quarter in 2012, the company posted ($0.11) earnings per share. The company’s revenue for the quarter was down 74.0% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post $-1.03 earnings per share for the current fiscal year.

    Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.37+0.04(+0.92%)Sep 30 4:00 PMEDT